TR200102225T2 - Diaryl derivatives and their use as drugs. - Google Patents

Diaryl derivatives and their use as drugs.

Info

Publication number
TR200102225T2
TR200102225T2 TR2001/02225T TR200102225T TR200102225T2 TR 200102225 T2 TR200102225 T2 TR 200102225T2 TR 2001/02225 T TR2001/02225 T TR 2001/02225T TR 200102225 T TR200102225 T TR 200102225T TR 200102225 T2 TR200102225 T2 TR 200102225T2
Authority
TR
Turkey
Prior art keywords
halogen
hydrogen
optionally substituted
alkyl
nr5r6
Prior art date
Application number
TR2001/02225T
Other languages
Turkish (tr)
Inventor
Jaana Kukkola Paivi
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TR200102225T2 publication Critical patent/TR200102225T2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/67—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)

Abstract

Asagidaki formüle sahip bilesikler ve bunlarin, farmasötik olarak kabul edilebilir tuzlari olup, FORMÜL söz konusu formül içersindeki, W;O, S, S(O)veya S(O)2'dir, X;-SR4, -S(O)R4 veya -S(O)2R4,-S(O)2NR5R6'dir veya X; -C(O)NR5R6'nin, 3'-, 4'- veya 5'-pozisyonunda konumlandirilmasi sartiyla, -C(O)NR5R6'dir, Y; O veya H2'dir; Z; hidrojen, halojen, hidroksi, istege bagli olarak substitüsyonlu alkoksi, aralkoksi, asiloksi veya alkoksikarboniloksidir, R;hidrojen, halojen, triflorometil, düsük alkil veya sikloalkildir, R1; hidroksi, istege bagli olarak substitüsyonlu alkoksi, ariloksi, heteroariloksi, aralkoksi, sikaloalkoksi, heteroaralkoksi veya -NR5R6'dir, R2; hidrojen, halojen veya alkildir, R3; halojen veya alkildir, R4; istege bagli olarak subsstitüssyonlu alkil, aril, aralkil, heteroaralkil veya heteroarildir, R5, R6 ve R7; bagimsiz olarak, hidrojen, istege bagli olarak substitüsyonlu alkil, sikloalkil, aril, aralkil, heteroaril veya heteroaralThe compounds of the formula below and their pharmaceutically acceptable salts are in the formula wherein W is O, S, S (O) or S (O) 2, X; -SR4, -S (O) R4 or -S (O) 2R4, -S (O) 2NR5R6, or X; -C (O) NR5R6, provided that -C (O) NR5R6 is positioned at the 3'-, 4'- or 5'-position, Y; O or H2; Z; hydrogen, halogen, hydroxy, optionally substituted alkoxy, aralkoxy, acyloxy or alkoxycarbonyloxy, R is hydrogen, halogen, trifluoromethyl, lower alkyl or cycloalkyl, R1; hydroxy is optionally substituted alkoxy, aryloxy, heteroaryloxy, aralkoxy, sikaloalkoxy, heteroaralkoxy or -NR5R6, R2; is hydrogen, halogen or alkyl, R3; is halogen or alkyl, R4; optionally substituted alkyl, aryl, aralkyl, heteroaralkyl or heteroaryl, R5, R6 and R7; independently, hydrogen, optionally substituted alkyl, cycloalkyl, aryl, aralkyl, heteroaryl or heteroaral

TR2001/02225T 1999-03-29 2000-03-27 Diaryl derivatives and their use as drugs. TR200102225T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28010599A 1999-03-29 1999-03-29

Publications (1)

Publication Number Publication Date
TR200102225T2 true TR200102225T2 (en) 2002-01-21

Family

ID=23071698

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/02225T TR200102225T2 (en) 1999-03-29 2000-03-27 Diaryl derivatives and their use as drugs.

Country Status (21)

Country Link
EP (1) EP1165502A1 (en)
JP (1) JP2002540189A (en)
KR (1) KR20010105394A (en)
CN (1) CN1345309A (en)
AU (1) AU4290800A (en)
BR (1) BR0009431A (en)
CA (1) CA2361016A1 (en)
CO (1) CO5160290A1 (en)
CZ (1) CZ20013449A3 (en)
HK (1) HK1042692A1 (en)
HU (1) HUP0200588A2 (en)
IL (1) IL144637A0 (en)
MX (1) MXPA01009843A (en)
NO (1) NO20014702L (en)
NZ (1) NZ514062A (en)
PE (1) PE20001587A1 (en)
PL (1) PL349355A1 (en)
RU (1) RU2001126579A (en)
SK (1) SK13812001A3 (en)
TR (1) TR200102225T2 (en)
WO (1) WO2000058279A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2001002259A0 (en) 1999-03-01 2001-09-30 Pfizer Prod Inc Oxamic acids and derivatives as thyroid receptor ligands.
US6790978B2 (en) 1999-03-29 2004-09-14 Novartis Ag Thyromimetic organic compounds
PL201790B1 (en) 2000-02-17 2009-05-29 Bristol Myers Squibb Co Aniline-derived ligands for the thyroid receptor
US6664291B2 (en) 2000-03-31 2003-12-16 Pfizer, Inc. Malonamic acids and derivatives thereof as thyroid receptor ligands
PL358596A1 (en) * 2000-03-31 2004-08-09 Pfizer Products Inc. Malonamic acids and derivatives thereof as thyroid receptor ligands
AU4884701A (en) * 2000-05-12 2001-11-20 Kissei Pharmaceutical Co. Ltd. Malonanilic acid derivatives, medicinal compositions containing the same and usethereof
US6395784B1 (en) 2000-06-07 2002-05-28 Bristol-Myers Squibb Company Benzamide ligands for the thyroid receptor
DE10038007A1 (en) 2000-08-04 2002-02-14 Bayer Ag New amino and amido diphenyl ethers for drugs
DE10046029A1 (en) 2000-09-18 2002-03-28 Bayer Ag indazoles
AU2002223626A1 (en) * 2000-10-20 2002-04-29 Novartis Ag Combinations of a thyromimetic compound and a statin
WO2002051805A1 (en) * 2000-12-27 2002-07-04 Bayer Aktiengesellschaft Indole derivatives as ligands of thyroid receptors
US6777442B2 (en) 2001-03-12 2004-08-17 Bayer Aktiengesellschaft Diphenyl derivatives
DE10122443A1 (en) * 2001-05-09 2002-11-14 Bayer Ag Amido-diphenyl derivatives
US6777443B2 (en) 2001-05-15 2004-08-17 Novartis Ag Dipeptide derivatives
DK1262177T3 (en) * 2001-05-31 2006-11-20 Pfizer Prod Inc Medical use of thyromimetic compounds for the treatment of hair loss and compositions
DE10131462A1 (en) * 2001-06-29 2003-01-09 Bayer Ag Phenol derivatives
ES2253495T3 (en) 2001-09-26 2006-06-01 Pfizer Products Inc. INDO CARBOXILIC ACIDS AS LIGHTING OF THYROID RECEPTORS.
US6818766B2 (en) 2002-10-02 2004-11-16 Synthon Bv Process for making bicalutamide and intermediates thereof
WO2006128058A2 (en) 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
CA2546601A1 (en) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
JP2007536348A (en) * 2004-05-05 2007-12-13 ノボ　ノルディスク　アクティーゼルスカブ Sulfonamide derivatives
RU2416608C2 (en) 2004-08-06 2011-04-20 Оцука Фармасьютикал Ко., Лтд. Aromatic compound
PL1957073T3 (en) 2005-12-05 2014-09-30 Otsuka Pharma Co Ltd Medicinal drug
UA95978C2 (en) 2006-10-02 2011-09-26 Оцука Фармас'Ютікел Ко., Лтд. Stat3/5 activation inhibitor
WO2009133834A1 (en) * 2008-04-28 2009-11-05 塩野義製薬株式会社 Keto-amide derivative having inhibitory activity on endothelial lipase
TW201512171A (en) 2013-04-19 2015-04-01 Pfizer Ltd Chemical compounds
CN104193699B (en) * 2014-08-14 2016-05-25 嘉兴特科罗生物科技有限公司 A kind of micromolecular compound and synthetic method and application
MX2019005730A (en) 2016-11-21 2019-10-21 Viking Therapeutics Inc Method of treating glycogen storage disease.
EA201992703A1 (en) 2017-06-05 2020-04-15 Вайкинг Терапьютикс, Инк. COMPOSITIONS FOR TREATING FIBROSIS
EP3768690A4 (en) 2018-03-22 2021-11-24 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound
WO2020117962A1 (en) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
CN112300133B (en) * 2019-07-31 2024-07-30 深圳微芯生物科技股份有限公司 Heterocyclic compound and application thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0580550T3 (en) * 1992-07-21 1998-02-02 Ciba Geigy Ag Oxamic acid derivatives as hypercholesterolemic agents

Also Published As

Publication number Publication date
PE20001587A1 (en) 2001-01-31
PL349355A1 (en) 2002-07-15
AU4290800A (en) 2000-10-16
NO20014702D0 (en) 2001-09-27
BR0009431A (en) 2002-01-08
MXPA01009843A (en) 2002-05-06
CZ20013449A3 (en) 2001-12-12
HUP0200588A2 (en) 2002-07-29
JP2002540189A (en) 2002-11-26
NO20014702L (en) 2001-09-27
IL144637A0 (en) 2002-05-23
HK1042692A1 (en) 2002-08-23
NZ514062A (en) 2001-09-28
WO2000058279A1 (en) 2000-10-05
SK13812001A3 (en) 2002-04-04
RU2001126579A (en) 2004-02-27
CO5160290A1 (en) 2002-05-30
CA2361016A1 (en) 2000-10-05
KR20010105394A (en) 2001-11-28
EP1165502A1 (en) 2002-01-02
CN1345309A (en) 2002-04-17

Similar Documents

Publication Publication Date Title
TR200102225T2 (en) Diaryl derivatives and their use as drugs.
TW347387B (en) Piperidine derivatives
NZ514873A (en) 4,5,6,7-tetrahydroindazole derivatives as antitumor agents
DE60102815D1 (en) 7-SUBSTITUTED CONDENSED RING TETRAZYCLINE COMPOUNDS
TW256835B (en)
AU3688193A (en) 1,2,4-oxadiazolyl-phenoxyalkylisoxazoles and their use as antiviral agents
CA2226894A1 (en) 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
ATE172463T1 (en) PYRROLOCARBAZOLE
DE69830045D1 (en) ARYLPIPERIDINOPROPANOL AND ARYLPIPERAZINOPROPANOL DERIVATIVES AND THE SAME CONTAINING PHARMACEUTICALS
NO985335L (en) 2,4-diaminopyrimidine
NZ308398A (en) 2-amino benzoxazin-4-one derivatives and medicaments
ATE231487T1 (en) 2-PHENOXYANILINE DERIVATIVES
AU7810787A (en) 6-{2-(3-phenoxy-2-hydroxy-propylamino)-propyl-amino}-5- methyl-pyrizine-3-one derivatives useful as antihyper- tensive agents
CA2452036A1 (en) 6-'2-(phosphonomethoxy) alkoxy pyrimidine derivatives having antiviral activity
NZ326675A (en) Oxazoline arthropodicides
JO2307B1 (en) Pyrimidine derivatives
MXPA03003971A (en) Indole derivatives as pde5-inhibitors.
TR200101808T2 (en) 3-tetrahydropyridine-4-yl indoles for the treatment of psychotic diseases
EP1203763A3 (en) Beta-hydroxyalkylamides, their use and a process for their synthesis
CA2283083A1 (en) Use of 2,3,4,5-tetrahydro-1h-3-benzazepines for the manufacture of a pharmaceutical composition for the treatment of sleep disorders
DE69810622D1 (en) NAPHTHOTHIAZOLONE DERIVATIVES THAT AFFECT DOPAMINERGEN RECEPTOR D 3
AU2406700A (en) 3,4-dihydro-2h-benzo(1,4)oxazinyl-methyl(3-(1h-indol-3-yl)-a kyl)-amines
ATE215082T1 (en) HERBOXIDIA DERIVATIVES AND THEIR PRODUCTION FROM A STREPTOMYCES GEX1 CULTURE
NZ332713A (en) Substituted 1,3-benzodioxoles and use as antidiabetic, antihyperglycemic, and antiobesity agents
HUP0203835A2 (en) Pyrimidine derivatives, process for preparing the derivatives and drugs containing the same as the active ingredient